請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/71332
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 簡穎秀 | |
dc.contributor.author | Zheying Liu | en |
dc.contributor.author | 劉喆瑩 | zh_TW |
dc.date.accessioned | 2021-06-17T05:58:59Z | - |
dc.date.available | 2019-06-23 | |
dc.date.copyright | 2019-03-05 | |
dc.date.issued | 2019 | |
dc.date.submitted | 2019-02-14 | |
dc.identifier.citation | 1. Mendell, J.R. and M. Lloyd‐Puryear, Report of MDA muscle disease symposium on newborn screening for Duchenne muscular dystrophy. Muscle & nerve, 2013. 48(1): p. 21-26.
2. Mendell, J.R., et al., Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann Neurol, 2012. 71(3): p. 304-13. 3. Scheuerbrandt, G., et al., Screening for Duchenne muscular dystrophy: an improved screening test for creatine kinase and its application in an infant screening program. Muscle & Nerve: Official Journal of the American Association of Electrodiagnostic Medicine, 1986. 9(1): p. 11-23. 4. Koenig, M., et al., Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell, 1987. 50(3): p. 509-517. 5. Hoffman, E.P., R.H. Brown Jr, and L.M. Kunkel, Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell, 1987. 51(6): p. 919-928. 6. Ciafaloni, E., et al., Delayed Diagnosis in Duchenne Muscular Dystrophy- Data from the Muscular Dystrophy Surveillance, Tracking, and Research Network. The Journal of pediatrics, 2009. 155(3): p. 380-5. 7. Bushby, K., et al., Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. The Lancet Neurology, 2010. 9(1): p. 77-93. 8. Verma, S., Y. Anziska, and J. Cracco, Review of Duchenne muscular dystrophy (DMD) for the pediatricians in the community. Clinical pediatrics, 2010. 49(11): p. 1011-1017. 9. Emery, A.E., The muscular dystrophies. The Lancet, 2002. 359(9307): p. 687-695. 10. Hoogerwaard, E., et al., Signs and symptoms of Duchenne muscular dystrophy and Becker muscular dystrophy among carriers in The Netherlands: a cohort study. Lancet (London, England), 1999. 353(9170): p. 2116-2119. 11. Hoogerwaard, E., et al., Cardiac involvement in carriers of Duchenne and Becker muscular dystrophy. Neuromuscular Disorders, 1999. 9(5): p. 347-351. 12. HALDANE, B.J., Mutation in the sex‐linked recessive type of muscular dystrophy. A possible sex difference. Annals of human genetics, 1956. 20(4): p. 344-347. 13. Aartsma‐Rus, A., et al., Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading‐frame rule. Muscle & Nerve: Official Journal of the American Association of Electrodiagnostic Medicine, 2006. 34(2): p. 135-144. 14. Lalic, T., et al., Deletion and duplication screening in the DMD gene using MLPA. European journal of human genetics, 2005. 13(11): p. 1231. 15. Hwa, H.-L., et al., Multiplex ligation-dependent probe amplification identification of deletions and duplications of the Duchenne muscular dystrophy gene in Taiwanese subjects. Journal of the Formosan Medical Association, 2007. 106(5): p. 339-346. 16. Hegde, M.R., et al., Microarray‐based mutation detection in the dystrophin gene. Human mutation, 2008. 29(9): p. 1091-1099. 17. Falzarano, M.S., et al., Duchenne Muscular Dystrophy: From Diagnosis to Therapy. Molecules, 2015. 20(10): p. 18168-84. 18. Mendell, J.R., et al., Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine, 1989. 320(24): p. 1592-1597. 19. Griggs, R., et al., Duchenne dystrophy randomized, controlled trial of prednisone (18 months) and azathioprine (12 months). Neurology, 1993. 43(3 Part 1): p. 520-520. 20. Fenichel, G., et al., Long‐term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology, 1991. 41(12): p. 1874-1874. 21. Shimizu-Motohashi, Y., et al., Restoring Dystrophin Expression in Duchenne Muscular Dystrophy: Current Status of Therapeutic Approaches. Journal of Personalized Medicine, 2019. 9(1). 22. Flanigan, K.M., et al., Rapid direct sequence analysis of the dystrophin gene. The American Journal of Human Genetics, 2003. 72(4): p. 931-939. 23. Malik, V., et al., Aminoglycoside-induced mutation suppression (stop codon readthrough) as a therapeutic strategy for Duchenne muscular dystrophy. Therapeutic advances in neurological disorders, 2010. 3(6): p. 379-389. 24. Finkel, R.S., et al., Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy. PloS one, 2013. 8(12): p. e81302. 25. Bushby, K., et al., Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle & nerve, 2014. 50(4): p. 477-487. 26. Kayali, R., et al., Read-through compound 13 restores dystrophin expression and improves muscle function in the mdx mouse model for Duchenne muscular dystrophy. Human molecular genetics, 2012. 21(18): p. 4007-4020. 27. Haas, M., et al., European Medicines Agency review of ataluren for the treatment of ambulant patients aged 5 years and older with Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene. Neuromuscular Disorders, 2015. 25(1): p. 5-13. 28. Bladen, C.L., et al., The TREAT‐NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. Human mutation, 2015. 36(4): p. 395-402. 29. Lu, Q.-L., et al., The status of exon skipping as a therapeutic approach to duchenne muscular dystrophy. Molecular Therapy, 2011. 19(1): p. 9-15. 30. Hollegaard, M.V., et al., Archived neonatal dried blood spot samples can be used for accurate whole genome and exome-targeted next-generation sequencing. Mol Genet Metab, 2013. 110(1-2): p. 65-72. 31. Winkel, B.G., et al., Whole-genome amplified DNA from stored dried blood spots is reliable in high resolution melting curve and sequencing analysis. BMC Med Genet, 2011. 12: p. 22. 32. Brusgaard, K., et al., High-Quality Exome Sequencing of Whole-Genome Amplified Neonatal Dried Blood Spot DNA. Plos One, 2016. 11(4). 33. St Julien, K.R., et al., High quality genome-wide genotyping from archived dried blood spots without DNA amplification. PLoS One, 2013. 8(5): p. e64710. 34. Bodian, D.L., et al., Utility of whole-genome sequencing for detection of newborn screening disorders in a population cohort of 1,696 neonates. Genet Med, 2016. 18(3): p. 221-30. 35. Lefterova, M.I., et al., Next-Generation Molecular Testing of Newborn Dried Blood Spots for Cystic Fibrosis. J Mol Diagn, 2016. 18(2): p. 267-82. 36. Boemer, F., et al., A next-generation newborn screening pilot study: NGS on dried blood spots detects causal mutations in patients with inherited metabolic diseases. Sci Rep, 2017. 7(1): p. 17641. 37. Ndlovu, B., et al., Use of dried blood spots for the determination of genetic variation of interleukin‐10, killer immunoglobulin‐like receptor and HLA class I genes. Tissue antigens, 2012. 79(2): p. 114-122. 38. Lim, B.C., et al., Genetic diagnosis of Duchenne and Becker muscular dystrophy using next-generation sequencing technology: comprehensive mutational search in a single platform. J Med Genet, 2011. 48(11): p. 731-6. 39. Wei, X., et al., Targeted next-generation sequencing as a comprehensive test for patients with and female carriers of DMD/BMD: a multi-population diagnostic study. European Journal of Human Genetics, 2014. 22(1): p. 110. 40. Wang, L.-Y., et al., Newborn screening for citrin deficiency and carnitine uptake defect using second-tier molecular tests. BMC medical genetics, 2013. 14(1): p. 24. 41. Thorvaldsdottir, H., J.T. Robinson, and J.P. Mesirov, Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform, 2013. 14(2): p. 178-92. 42. Bank, S., et al., High-quality and-quantity DNA extraction from frozen archival blood clots for genotyping of single-nucleotide polymorphisms. Genetic testing and molecular biomarkers, 2013. 17(6): p. 501-503. 43. Zellweger, H. and A. Antonik, Newborn screening for Duchenne muscular dystrophy. Pediatrics, 1975. 55(1): p. 30-34. 44. Drummond, L., Creatine phosphokinase levels in the newborn and their use in screening for Duchenne muscular dystrophy. Archives of disease in childhood, 1979. 54(5): p. 362-366. 45. Skinner, R., et al., Feasibility of neonatal screening for Duchenne muscular dystrophy. Journal of medical genetics, 1982. 19(1): p. 1-3. 46. Greenberg, C., et al., Gene studies in newborn males with Duchenne muscular dystrophy detected by neonatal screening. The Lancet, 1988. 332(8608): p. 425-427. 47. Plauchu, H., et al., Duchenne muscular dystrophy: neonatal screening and prenatal diagnosis. The Lancet, 1989. 333(8639): p. 669. 48. EW, N., New technologies in newborn screening. Yale J Biol Med, 1991. 64: p. 21-24. 49. Bradley, D., E. Parsons, and A. Clarke, Experience with screening newborns for Duchenne muscular dystrophy in Wales. Bmj, 1993. 306(6874): p. 357-360. 50. Drousiotou, A., et al., Neonatal screening for Duchenne muscular dystrophy: a novel semiquantitative application of the bioluminescence test for creatine kinase in a pilot national program in Cyprus. Genetic testing, 1998. 2(1): p. 55-60. 51. Eyskens, F. and E. Philips, GP 10 10 Newborn screening for Duchenne muscular dystrophy. The experience in the province of Antwerp. Neuromuscular Disorders, 2006. 16(9): p. 721. 52. Moat, S.J., et al., Newborn bloodspot screening for Duchenne muscular dystrophy: 21 years experience in Wales (UK). Eur J Hum Genet, 2013. 21(10): p. 1049-53. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/71332 | - |
dc.description.abstract | 背景
裘馨氏肌肉失養症(Duchenne muscular dystrophy, DMD)是一種X染色體性聯隱性遺傳的進行性肌肉萎縮症,全世界發生率約每5000名男性新生兒中即有1例。多數患者在9至12歲時需依賴輪椅代步,並常因心肺併發症而在20多歲死亡。裘馨氏肌肉失養症和貝克型肌肉萎縮症(Becker muscular dystrophy, BMD)的傳統基因診斷常需要至少兩種以上的分析方法來檢測突變,既耗時又費力。鑑於巨大的肌肉萎縮蛋白基因(dystrophin gene, DMD gene)以及其複雜的突變模式特徵,DMD基因可視為高通量測序的潛在候選者。此外,基於證據顯示早期診斷有助於接受早期皮質類固醇治療而改善病程,以及近期基因治療的發明,DMD亦有機會被納入全國性新生兒篩檢疾病之中。我們希望建立一個實驗方案,利用新生兒篩檢濾紙血片中萃取出理想品質與數量、不需經擴增的去氧核糖核酸(deoxyribonucleic acid, DNA),經由目標區間次世代定序(targeted next generation sequencing)的技術成功進行肌肉萎縮蛋白基因分析。 材料和方法 我們收集由健康成年志願者、DMD確診患者和新生兒篩檢存檔濾紙血片組成的10個樣本。該研究分為兩個階段。第一階段為微調從濾紙血片萃取的DNA實驗步驟,及比較不同的DNA商業萃取試劑套組之純度及產量:Gentra Puregene Blood Kit(QIAGEN)、QIAamp DNA Micro Kit(QIAGEN)和QIAamp DNA Investigator Kit(QIAGEN)。第二階段包括調整標靶次世代定序實驗步驟來分析肌肉萎縮蛋白基因,以及測試各種市售樣本庫製備(library preparation)試劑套組,如KAPA DNA Library Preparation Kits (Kapa Biosystems, Roche)和ThruPLEX DNA-seq Kit (Rubicon Genomics),以及各種市售標的外顯子組捕獲(target exome capture)套組,如SeqCap EZ Exome Library v2.0(Roche Nimblegen)和xGen Lockdown Probes(IDT),來優化實驗方案。 結果 萃取出DNA的初始濃度在2.11至131 ng/uL波動。使用QIAamp DNA Investigator Ki可獲得最高產量,平均值為26.29 ng/uL(範圍為3.48-131.00 ng/uL)。由A260/A280比率測試的純度平均值為1.92(範圍為0.74-1.99)。樣本庫的濃度在13.3至45.8 ng/uL之間變化。QIAamp DNA Investigator Kit和KAPA DNA Library Preparation Kits的組合可產生最高濃度的DNA樣本庫,平均值為35.14 ng/uL(範圍為17.2-45.8 ng/uL)。ThruPLEX DNA-seq Kit和KAPA DNA Library Preparation Kits的覆蓋深度分別為88.3×(範圍為32.4×-144.2×)和86.81×(範圍為22.0×-244.5×)。KAPA DNA Library Preparation Kits產出較低的PCR重複率(polymerase chain reaction duplication rate),平均值為0.86(範圍為0.7-1.7)。而比較兩組商業標的探針,xGen Lockdown Probes顯示有較高的覆蓋DMD外顯子組的效率,最高可達244.5×,亦可得到較低的平均PCR重複率(2.89,範圍為0.7-18.3)。然而,比對回exon上的讀序百分比( on-target reads)在這兩種標的外顯子組捕獲技術中表現皆不佳,僅能達到10。 結論 我們成功建立一可靠診斷策略,利用QIAamp DNA Investigator Kit可由濾紙血片萃取出理想品質與數量、不需經擴增的DNA,接續使用KAPA DNA Library Preparation Kits及xGen Lockdown Probes製備樣本庫後,將可在Illumina MiSeq測序儀上有效鑑定DMD基因。 | zh_TW |
dc.description.abstract | Background
Duchenne muscular dystrophy (DMD) is an X-linked disorder with an incidence of approximately 1 in every 5000 male births worldwide. The majority of DMD patients become wheelchair-bound between ages 9 and 12 years and die at their early 20’s due to cardiopulmonary complications. The traditional genetic diagnosis of Duchenne and Becker muscular dystrophies requires two or more analytical methods to detect mutations and is cost-intensive and time-consuming. Dystrophin gene (DMD) is potentially an acceptable candidate for high throughput sequencing in view of its characteristics of the complex mutational spectrum and the largest size of the human genome. Moreover, based on the bright evidence that early corticosteroid treatment improves outcomes and on new genetic therapies that require early diagnosis for effectiveness, DMD has emerged as a promising candidate for the recommended universal screening panel. We demonstrated a protocol that unamplified DNA (deoxyribonucleic acid) extracted from archived DBS could yield adequate quality and quantity input DNA for DMD gene analysis by targeted exome sequencing. Material and method Ten subjects composed of healthy adult volunteers, patients with diagnosed DMD, and archived dried blood spots (DBS) samples were enrolled. This study was conducted into two phases. Phase I was composed of modification of steps of DNA extraction and comparison of the different commercial DNA extraction kits, Gentra Puregene Blood Kit (QIAGEN), QIAamp DNA Micro Kit (QIAGEN) and QIAamp DNA Investigator Kit (QIAGEN). Phase II consisted of adjustment of process of DMD gene analysis by targeted sequencing and testing of various commercially available library preparation kits, KAPA DNA Library Preparation Kits (Kapa Biosystems, Roche) and ThruPLEX DNA-seq Kit (Rubicon Genomics), and exome capture probes, SeqCap EZ Exome Library v2.0 (Roche Nimblegen) and xGen Lockdown Probes (IDT) for optimization of the protocol. Results The concentration of extracted genomic DNA were fluctuated from 2.11 to 131 ng/uL. The highest yields were obtained using the QIAamp DNA Investigator Kit with a mean of 26.29 ng/uL (range, 3.48–131.00 ng/uL). The quality evaluated by A260/A280 ratio was 0.74-1.99. The concentrations of the libraries were variable from 13.3 to 45.8 ng/uL. The highest concentration of DNA library was constructed by combination of the QIAamp DNA Investigator Kit and KAPA DNA Library Preparation Kits with a mean of 35.14 ng/uL (range, 17.2-45.8 ng/uL). The depth of coverage in ThruPLEX DNA-seq Kit and KAPA DNA Library Preparation Kits were 88.3× (range, 32.4×-144.2×) and 86.81× (range, 22.0×-244.5×), respectively. The low PCR (polymerase chain reaction) duplicate rate was yielded by KAPA DNA Library Preparation Kits with a mean of 0.86% (range, 0.7%-1.7%). The xGen Lockdown Probes revealed greater efficiency in covering the DMD exome with a maximum of 244.5× with lower mean duplicate rate (2.89%, range 0.7%-18.3%) than those with SeqCap EZ Exome Library v2.0. However, on target percentage were both poor in these two exome capture technologies and could only achieve 10%. Conclusion We demonstrated the use of QIAamp DNA Investigator Kit for DBS with Illumina MiSeq sequencers for targeted sequencing by KAPA DNA Library Preparation Kits and xGen Lockdown Probes is a reliable diagnostic strategy to identify DMD gene. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T05:58:59Z (GMT). No. of bitstreams: 1 ntu-108-P04448007-1.pdf: 1923187 bytes, checksum: ffc9386d806d43c88697927f0fed580d (MD5) Previous issue date: 2019 | en |
dc.description.tableofcontents | Acknowledgement i
Abstract (Chinese) ii Abstract (English) v Contents viii List of Figures x List of Tables xii Abbreviations xiii Chapter 1 Introduction 1 1.1 Duchenne Muscular Dystrophy and Becker muscular dystrophy 1 1.1.1 Duchenne muscular dystrophy 1 1.1.2 Becker muscular dystrophy 3 1.2 Molecular testing of Duchenne and Becker muscular dystrophy 3 1.3 Treatment in Duchenne and Becker muscular dystrophy 5 1.4 Newborn screening in Duchenne muscular dystrophy 7 1.5 Motivation 9 Chapter 2 Materials and Methods 12 2.1 Patient enrollment and sample collection 12 2.2 DNA extraction, amplification, and quantification 12 2.3 Preparation of sequencing libraries 14 2.4 Sequencing and primary data processing 15 Chapter 3 Results 16 3.1 Established DNA extraction methods 17 3.2 Performance of DNA extracted from dried blood spots using targeted sequencing 18 3.2.1 Sequencing library preparation 18 3.2.2 Target region captures and sequencing 20 3.2.3 Mean depth of coverage 20 Chapter 4 Discussion 22 Chapter 5 Conclusion 28 References 30 Supplemental information 35 | |
dc.language.iso | en | |
dc.title | 建立以濾紙血片檢測裘馨氏肌肉失養症基因的方法 | zh_TW |
dc.title | Establishment of an NGS method for dystrophin gene analysis from dried blood spots | en |
dc.type | Thesis | |
dc.date.schoolyear | 107-1 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 胡務亮,李妮鍾 | |
dc.subject.keyword | 裘馨氏肌肉失養症,肌肉萎縮蛋白基因,濾紙血片,目標區間外顯子組定序,基因診斷, | zh_TW |
dc.subject.keyword | Duchenne muscular dystrophy,dystrophin gene,DMD,dried blood spots,targeted exome sequencing,targeted NGS,genetic diagnosis, | en |
dc.relation.page | 57 | |
dc.identifier.doi | 10.6342/NTU201900590 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2019-02-14 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 分子醫學研究所 | zh_TW |
顯示於系所單位: | 分子醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-108-1.pdf 目前未授權公開取用 | 1.88 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。